This article is more than 5 years old. Information may no longer be current.

STAAR reports strong growth in Q2 refractive product sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MONROVIA, Calif. — STAAR Surgical Co. reported improved performance for the second quarter 2006, driven by refractive product sales, according to a press release.

Second quarter product sales totaled approximately $14.6 million, a 4.7% increase over the second quarter 2005 and a 9.4% increase over the first quarter 2006. For the first six months of 2006, product sales increased 1% over the same period last year to total approximately $27.9 million, according to the release.

The company achieved 106.9% year-over-year sales growth in its refractive business, totaling approximately $3.45 million. Company officials attributed the growth to increased sales of STAAR’s Visian ICL, which grew 76%. Visian ICL and refractive support product sales in the United States totaled approximately $1.3 million for the quarter, with U.S. sales of ICLs totaling approximately $1.2 million.

International ICL and toric ICL sales grew 26.3% over the second quarter 2005 to approximately $2.1 million. Year-to-date international sales of ICLs and toric ICLs grew 24.9% to approximately $3.8 million.

Cataract product sales in the U.S. declined 8.1% for the quarter compared with the same period of 2005, but grew 7.4% over the first quarter 2006, according to the release.